This article highlights recent research on breast cancer, lung cancer, melanoma, head and neck cancer, and hematologic malignancies.

The National Institutes of Health (NIH) can continue withholding funding for terminated research grants, the Supreme Court has ruled. 1,2 The court’s decision allows the NIH to withhold the funding ...

Two researchers describe their experiences with cancer research funding cuts due to the Trump administration’s policies and actions.

The “early promising clinical outcomes” provide a strong basis for further investigation of upright image-guided adaptive proton therapy, according to researchers.

The main implication of our study is support for incorporating quadruplet regimens into new guidelines for the management of transplant-ineligible patients newly diagnosed multiple myeloma,” the ...

Only patients who received rituximab, ipilimumab plus nivolumab, and trastuzumab plus pertuzumab had infusion-related reactions in the real-world cohort.

The ASPR must update its 2022 list of 86 essential medicines and provide a plan to store and maintain a 6-month supply of APIs for drugs on the updated list, the order states.

“he introduction of effective cancer innovations increased population-level health among patients with advanced lung cancer and melanoma but also widened the survival gap across county-level income ...

The FDA has authorized the ArteraAI Prostate Test to prognosticate long-term outcomes in patients with non-metastatic prostate cancer.

An analysis of more than 13 million EHR notes revealed evidence suggesting racial bias in how doctors document patient credibility.

Childhood cancer survivors with diabetes mellitus have an increased risk of neurocognitive impairment, a study suggests.

Subspecialization in oncology is increasing in the United States, but it varies across cancer types and regions, data suggest.